These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23884268)

  • 1. Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy.
    Patil AS; Dotters-Katz SK; Metjian AD; James AH; Swamy GK
    Obstet Gynecol; 2013 Aug; 122(2 Pt 2):483-485. PubMed ID: 23884268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
    Raval JS; Redner RL; Kiss JE
    J Clin Apher; 2013 Aug; 28(4):321-4. PubMed ID: 23450778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description.
    Rosa María RN; Laura RL; Ángeles PB; Laura LB
    Platelets; 2020; 31(3):403-406. PubMed ID: 31116059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romiplostim for management of refractory immune thrombocytopenic purpura in the immediate postpartum period.
    Patras A; Figueroa R; Singh AP; Madan I
    BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32430352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic immune thrombocytopenia in children with romiplostim.
    Chaturvedi S; McCrae KR
    Lancet; 2016 Jul; 388(10039):4-6. PubMed ID: 27103125
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J; Katsandris A; Raptis SD; Mantzourani M
    Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura.
    Gardiner EE; Thom JY; Al-Tamimi M; Hughes A; Berndt MC; Andrews RK; Baker RI
    Br J Haematol; 2010 May; 149(4):625-8. PubMed ID: 20148887
    [No Abstract]   [Full Text] [Related]  

  • 12. Remissions after long-term use of romiplostim for immune thrombocytopenia.
    Marshall AL; Scarpone R; De Greef M; Bird R; Kuter DJ
    Haematologica; 2016 Dec; 101(12):e476-e478. PubMed ID: 27587382
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.
    Mahat U; Talati R; Kodish E
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27706. PubMed ID: 30854752
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
    Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 16. Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy.
    Decroocq J; Marcellin L; Le Ray C; Willems L
    Obstet Gynecol; 2014 Aug; 124(2 Pt 2 Suppl 1):481-483. PubMed ID: 25004319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
    Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Iwato K; Okamoto S; Kurokawa M; Kirito K; Hashino S; Ninomiya H; Mori S; Yonemura Y; Usuki K; Wei H; Lizambri R
    Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
    López MF; Mingot ME; Valcárcel D; Vicente García V; Perrin A; Campos Tapias I
    Med Clin (Barc); 2015 May; 144(9):389-96. PubMed ID: 24565604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
    Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
    Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.